Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. Knight said the repayment was funded through strong cash flow generated by its operations in Canada and Latin America.
The repayment underscores the company's financial strength and operational efficiency, as it was able to retire the debt within months of drawing it. The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions, supporting the company's ongoing growth strategy across its pan-American pharmaceutical business. This financial flexibility is crucial for Knight as it pursues further acquisitions or in-licensing opportunities in Canada and Latin America.
The move also signals to investors that Knight's core business is generating sufficient cash to cover both operational needs and debt repayment, reducing leverage and interest expenses. The Paladin acquisition, which expanded Knight's portfolio in Latin America, appears to be integrating well, contributing to the strong cash flows. Knight's Latin American subsidiaries, operating under United Medical, Biotoscana Farma and Laboratorio LKM, are key drivers of this performance.
For more details on the announcement, the full press release can be viewed at https://ibn.fm/8eluB. Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its shares trade on the TSX under the symbol GUD. Additional information about the company is available at https://www.knighttx.com.
